Anatomy

Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million

Monday, May 17, 2021 - 9:01pm

In 2017, Concert received a one-time cash payment of $160 million upon closing the asset purchase, with the potential for $90 million in future milestones.

Key Points: 
  • In 2017, Concert received a one-time cash payment of $160 million upon closing the asset purchase, with the potential for $90 million in future milestones.
  • Concert\xe2\x80\x99s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition.
  • Concert is also assessing a number of earlier-stage pipeline candidates.
  • We specifically disclaim any obligation to update any forward-looking statements included in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005838/en/\n'

Shady Grove Fertility (SGF) Chief Medical Officer, Eric Widra, M.D., Hosts Educational Polycystic Ovary Syndrome (PCOS) Session at the 2021 American Fertility Expo

Monday, May 17, 2021 - 9:30pm

b'ROCKVILLE, Md., May 17, 2021 /PRNewswire-PRWeb/ --Women seeking more information about polycystic ovary syndrome (PCOS) and its effects on fertility are welcomed to join Shady Grove Fertility (SGF) Chief Medical Officer, Eric Widra, M.D.

Key Points: 
  • b'ROCKVILLE, Md., May 17, 2021 /PRNewswire-PRWeb/ --Women seeking more information about polycystic ovary syndrome (PCOS) and its effects on fertility are welcomed to join Shady Grove Fertility (SGF) Chief Medical Officer, Eric Widra, M.D.
  • , for his breakout session on the topic at the virtual American Fertility Expo on May 22, 2021.
  • "I\'m proud to shed light on PCOS during the American Fertility Expo so that women can become empowered with answers regarding the condition and the treatment options available to them.
  • SGF is among the founding partner practices of US Fertility , the largest physician-owned, physician-led partnership of top-tier fertility practices in the U.S.

AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

Monday, May 17, 2021 - 8:12pm

b'NATICK, Mass., May 17, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

Key Points: 
  • b'NATICK, Mass., May 17, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
  • The company previously received Orphan Drug designation for AIC100.\nThe FDA\'s Fast Track designation is designed to facilitate development and expedite review of drug candidates to treat serious conditions and address an unmet medical need.
  • Receipt of Fast Track designation provides grounds for more frequent interaction with the FDA throughout the drug development process for more rapid advancement, earlier approval and access for patients.\n"We are pleased to have received Fast Track designation for our first-in-human CAR T cell product currently being tested in patients with refractory thyroid cancer," remarked Eric von Hofe, President and COO of AffyImmune.
  • "It highlights the unmet need in treating refractory solid tumors and points to the potential of AIC100 to address that need.

Facial Lounge Announces an Iconic Partnership with IMD Health and Wellness

Monday, May 17, 2021 - 1:41pm

Facial Lounge Founder Amber Rose Johnson, who takes a holistic approach to skincare through her spa\'s signature custom vegan facial and lymphatic drainage facials, recently announced her partnership with celebrity-praised IMD Health and Wellness , founded by Irani Makimoto-Domino, in New York.

Key Points: 
  • Facial Lounge Founder Amber Rose Johnson, who takes a holistic approach to skincare through her spa\'s signature custom vegan facial and lymphatic drainage facials, recently announced her partnership with celebrity-praised IMD Health and Wellness , founded by Irani Makimoto-Domino, in New York.
  • Last year they opened a second location in Beverly Hills and brought in Facial Lounge May 2021.
  • IMD Health and Wellness will offer the infamous Facial Lounge custom vegan facial and Facial Lounge will offer IMD Health and Wellness\' signature lymphatic draining treatment, which calls for a magnesium thermal wrapped infrared sauna session followed by a signature lymphatic massage.
  • "Our partnership with Facial Lounge fits together so perfectly because we offer different services that complement each other well.

ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure

Monday, May 17, 2021 - 1:00pm

The single-center study evaluated 30 ADHF patients in mainstream setting (i.e., step-down unit, not critical care) who were treated with Aquadex therapy.

Key Points: 
  • The single-center study evaluated 30 ADHF patients in mainstream setting (i.e., step-down unit, not critical care) who were treated with Aquadex therapy.
  • Aquadex achieved gratifying symptom improvement by fluid removal without worsening renal function, and reduced heart failure readmission rates in this cohort of our most challenging patients.
  • \xe2\x80\x9cOur gentle ultrafiltration therapy is built to effectively remove fluid at a customizable rate, which is beneficial for fragile patients such as those with heart failure.
  • Presented at: Heart Failure Society of America Scientific Meeting; Sept. 30-Oct. 6, 2020 (virtual meeting).\nPresident, Chief Executive Officer and Chief Financial Officer, Nuwellis, Inc.\n'

Heart Failure Epidemiology Forecast Report 2021-2030 - Focus on United States, Germany, France, Italy, Spain, United Kingdom and Japan - ResearchAndMarkets.com

Monday, May 17, 2021 - 12:10pm

While, UK has the least number of cases with 728,547 in 2020.\nThere are several Heart Failure related comorbidities which include obesity, hyperlipidemia, metabolic syndrome, and others.

Key Points: 
  • While, UK has the least number of cases with 728,547 in 2020.\nThere are several Heart Failure related comorbidities which include obesity, hyperlipidemia, metabolic syndrome, and others.
  • Amongst them in the US, in 2020, 3,837,746, 2,237,179, 991,319, 1,626,382, 1,587,659, 3,097,871, and 2,065,247 cases were observed in Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Atrial Fibrillation, COPD, Ischemic heart disease, and Dilated cardiomyopathy.\nAge-specific data shows that the diagnosed prevalent cases are seen maximum in elderly patients (?
  • 85 age) this is due to the progressive aging of the population as well as improved and better survival after cardiac insults, such as myocardial infarction, especially in developed countries.\nHeart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age.
  • According to the analysis, in 2020, the estimated cases of HF were 2,478,297 in males and 2,684,822 in females, in the US.\nThe report covers the descriptive overview of HF, explaining its causes, symptoms, pathophysiology, and genetic basis.\nThe report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.\nThe report assesses the disease risk and burden and highlights the unmet needs of HF.\nThe report helps to recognize the growth opportunities in the 7MM with respect to the patient population.\nThe report provides the segmentation of the disease epidemiology for 7MM by Prevalent Population of HF, Diagnosed Prevalent Population of HF, Gender-specific diagnosed prevalent cases of HF, Age-specific diagnosed prevalent cases of HF, NYHA class-specific diagnosed prevalent cases of HF, Diagnosed prevalent cases of HF with Ejection Fraction, and Diagnosed Prevalent cases of HF associated with comorbidities.\n'

Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology’s 70th Annual Scientific Session

Saturday, May 15, 2021 - 5:15pm

At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales.

Key Points: 
  • At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales.
  • Moreover, a greater proportion of mavacamten patients achieved a very large, clinically meaningful improvement (\xe2\x89\xa520 points) in the KCCQ OSS, compared to placebo, 36% [33/92] vs. 15% [13/88].
  • A change of at least 5 points is required to be considered clinically significant.
  • Mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance.

Young Women with Chest Pain Wait Longer and Receive Less Urgent Care Than Men

Saturday, May 15, 2021 - 3:30pm

"\nThe study found young women were equally likely to arrive to the emergency department by ambulance as men.

Key Points: 
  • "\nThe study found young women were equally likely to arrive to the emergency department by ambulance as men.
  • Women in the study waited and average of 45 minutes to be evaluated by a provider while men were seen on average within 37 minutes.
  • These symptoms can include pain, pressure, or tightness in the chest, shortness of breath, nausea, indigestion, heartburn, sweating, lightheadedness, and fatigue.
  • "\nThe researchers were not able to determine why women with chest pain were treated differently than men.

REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual

Saturday, May 15, 2021 - 1:00pm

\xe2\x80\x9cThe potential benefit of increased serum EPA levels in reducing the composite of cardiovascular death or new heart failure requiring hospitalization in at-risk patients is a novel finding for icosapent ethyl and requires further prospective validation.

Key Points: 
  • \xe2\x80\x9cThe potential benefit of increased serum EPA levels in reducing the composite of cardiovascular death or new heart failure requiring hospitalization in at-risk patients is a novel finding for icosapent ethyl and requires further prospective validation.
  • New heart failure and new heart failure requiring hospitalization were prespecified tertiary endpoints and were not significant in the overall patient population.
  • \xe2\x80\x9cHeart failure, in particular, devastates patients, their families and economies with significant direct costs and societal impact.
  • ET to further discuss these and other VASCEPA-related findings presented during ACC.21, with replay available for a period of 14 days.

New Diagnostic Technology Showcased During Osteoporosis Awareness Month

Friday, May 14, 2021 - 10:54pm

"The portability and ease of use of REMS technology means screening can begin earlier, better positioning patients and their health care providers to take meaningful steps to prevent the onset of osteoporosis rather than to treat the disease once fractures begin to impact quality of life.

Key Points: 
  • "The portability and ease of use of REMS technology means screening can begin earlier, better positioning patients and their health care providers to take meaningful steps to prevent the onset of osteoporosis rather than to treat the disease once fractures begin to impact quality of life.
  • "\nMore than half of Americans age 50 and older have a high-risk of bone fracture, making osteoporosis and osteopenia an urgent public health issue.
  • It is especially prominent in women, as pregnancy and menopause can cause bone density loss.
  • Portable, diagnostic, radiation-free bone health densitometer - a safe, accurate, and cost-effective medical device elevating bone health awareness and treatment to mainstream medical care.